STOCKHOLM, Feb. 9, 2018 /PRNewswire/ --Fourth Quarter

  • Revenue increased by 15.2% to €152.7m (€132.5m). Organic revenue grew by 12.6%.
  • Operating profit amounted to €7.8m (€3.9m), representing an operating margin of 5.1% (2.9%).
  • Net profit amounted to €9.2m (€1.7m), which represents a net profit margin of 6.0% (1.3%).
  • Cash flow from operating activities amounted to €17.3m (€7.3m).
  • Basic/diluted earnings per share (EPS) was €0.067 (€0.008).
  • EBITDA increased by 28.1% to €14.6m (€11.4m), corresponding to an EBITDA margin of 9.6% (8.6%).
    Full Year
  • Revenue increased by 16.7% to €580.2m (€497.3m). Organic revenue grew by 14.5%.
  • Net profit amounted to €20.2m (€6.5m), which represents a net profit margin of 3.5% (1.3%).
  • EBITDA increased by 24.2% to €55.0m (€44.3m), corresponding to an EBITDA margin of 9.5% (8.9%). Excluding IPO costs expensed, EBITDA increased by 27.5% to €56.5m a margin of 9.7%.
  • Number of members increased by 15.2% reaching 1,024K members at 31 December 2017 (889K). Number of lab tests increased by 7.8% reaching 124.0m (115.0m) for the year.
  • The Board of Directors proposes that no dividend be paid for the 2017 financial year.

With this release, Medicover also announces another investment of €4.1m into MaxCure, which in addition to the €2.6m in January will bring Medicover's holding to 30.5%.

 

REVENUE AND EARNINGS

 

€ millions (€m)

 

Q4 2017

 

Q4 2016

 

Growth

 

FY 2017

 

FY 2016

 

Growth 

 

Revenue

 

152.7

 

132.5

 

15%

 

580.2

 

497.3

 

 

17%

 

Operating profit

 

7.8

 

3.9

 

100%

 

28.8

 

17.6

 

 

64%

 

Operating profit margin, %

 

5.1%

 

2.9%


 

5.0%

 

3.5%


 

Net profit

 

9.2

 

1.7

 

N/M

 

20.2

 

6.5

 

 

211%

 

Net profit margin, %

 

6.0%

 

1.3%


 

3.5%

 

1.3%


 

Earnings per share, €

 

0.067

 

0.008

 

N/M

 

0.157

 

0.046

 

 

241%

 

Diluted earnings per share, €

 

0.067

 

0.008

 

N/M

 

0.157

 

0.045

 

 

249%








 

EBITDA1

 

14.6

 

11.4

 

28%

 

55.0

 

44.3

 

 

24%

 

EBITDA margin, %1

 

9.6%

 

8.6%


 

9.5%

 

8.9%









[1] For Alternative Performance Measure definitions and reconciliations, refer to note 11

 

This information is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8.00 (CET) on 9 February 2018. This interim report and other information about Medicover, is available at medicover.com

For further information, please contact:

Paula Treutiger, Corporate Communications & Investor Relations, Director           

Phone: +46-73-66 6599
Mail: paula.treutiger@medicover.com

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medicover/r/year-end-report-january-december-2017,c2449022

The following files are available for download:


Source: Medicover